

Datasheet: 205009

BATCH NUMBER 165713

Description:	GOAT ANTI HUMAN IgA:RPE
Specificity:	IgA
Format:	RPE
Product Type:	Polyclonal Antibody
Isotype:	Polyclonal IgG
Quantity:	0.5 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry				

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form Purified IgG conjugated to R. Phycoerythrin (RPE) - liquid Max Ex/Em Fluorophore RPE 488nm laser Purified IgG prepared by affinity chromatography on pooled hu Buffer Solution Phosphate buffered saline Preservative Stabilizers Stabilizing agent (sucrose) 0.5 mg/ml				
Fluorophore Excitation Max (nm) Emission Max (nm) RPE 488nm laser 496 578 Preparation Purified IgG prepared by affinity chromatography on pooled hu Buffer Solution Phosphate buffered saline Preservative <0.1% Sodium Azide (NaN ₃) Stabilizers Stabilizing agent (sucrose) Approx. Protein Concentrations O.5 mg/ml	Target Species	Human		
Preparation Purified IgG prepared by affinity chromatography on pooled human Phosphate buffered saline Preservative Stabilisers Stabilizing agent (sucrose) Approx. Protein Concentrations Purified IgG prepared by affinity chromatography on pooled human pooled human properties along the properties of the properties o	Product Form	Purified IgG conjugate	ed to R. Phycoerythrin	(RPE) - liquid
Preparation Purified IgG prepared by affinity chromatography on pooled human Buffer Solution Phosphate buffered saline Preservative <0.1% Sodium Azide (NaN ₃) Stabilizers Stabilizing agent (sucrose) Approx. Protein Concentrations 0.5 mg/ml	Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
Buffer Solution Phosphate buffered saline Preservative <0.1% Sodium Azide (NaN ₃) Stabilizers Stabilizing agent (sucrose) Approx. Protein Concentrations 0.5 mg/ml		RPE 488nm laser	496	578
Preservative <0.1% Sodium Azide (NaN ₃) Stabilizers Stabilizing agent (sucrose) Approx. Protein Concentrations 0.5 mg/ml	Preparation	Purified IgG prepared	by affinity chromatog	raphy on pooled hur
Stabilisers Stabilizing agent (sucrose) Approx. Protein Concentrations 0.5 mg/ml	Buffer Solution	Phosphate buffered sa	aline	
Approx. Protein Concentrations O.5 mg/ml	Preservative	<0.1% Sodium Azide	(NaN ₃)	
Concentrations 0.5 mg/ml	Stabilisers	Stabilizing agent (suc	rose)	
mmunogen Human IgA.	Approx. Protein Concentrations	0.5 mg/ml		
3	lmmunogen	Human IgA.		

External Database Links	UniProt: P01876 Related reagents P01877 Related reagents Entrez Gene: 3493 IGHA1 Related reagents			
	3494 IGHA2 Related reagents			
RRID	AB_616850			
Specificity	Goat anti Human IgA antibody recognizes the heavy chain of human IgA as demonstrated by ELISA and Flow cytometry. IgA is the major catagory of antibody present in mucosal secretions and acts as a first line of defense against inhaled or ingested pathogens at the mucosal interface. IgA is also present in serum where it acts to eliminate pathogens via interaction with FcαR, also known as CD89. (Woof et al. 2004). Biotinylated Goat anti Human IgA antibody (205008) has been cross-adsorbed against human IgD, IgG and IgM to ensure class specificity.			
References	 Wright, A.K. et al. (2012) Human Nasal Challenge with Streptococcus pneumoniae Is Immunising in the Absence of Carriage. PLoS Pathog. 8: e1002622. Pennington, S.H. et al. (2016) Polysaccharide-specific Memory B-cells Predict Protection Against Experimental Human Pneumococcal Carriage. Am J Respir Crit Care Med. Jul 12. [Epub ahead of print] Turner, P.J. et al. (2020) Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children. Clin Exp Immunol. 199 (2): 109-118. Cole, M.E. et al. (2021) Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children. Clin Exp Immunol. 204 (1): 125-133. 			

Storage ### C DO NOT FREEZE This product is photosensitive and should be protected from light. | Guarantee | Guaranteed for 12 months from the date of despatch or until the date of expiry, whichever comes first. Please see label for expiry date. | Health And Safety | Material Safety Datasheet documentation #10045 available at: https://www.bio-rad-antibodies.com/SDS/205009 10045 | Regulatory | For research purposes only

Related Products

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)
 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

Fax: +1 919 878 3751 Fax: +44 (0)1865 852 739 Fax: +49 (0) 89 8090 95 50 To
Email: antibody_sales_us@bio-rad.com Email: antibody_sales_uk@bio-rad.com Email: antibody_sales_de@bio-rad.com Email: antibody_sales_de@bio-rad.com

batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M402042:220718'

Printed on 01 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint